Skip to main content
Erschienen in:

30.08.2016 | ORIGINAL ARTICLE

Beta-Blockers and Calcium Channel Blockers: First Line Agents

verfasst von: Isaac Pascual, Cesar Moris, Pablo Avanzas

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Beta-blockers and calcium channel blockers (CCB) are milestones in the treatment of stable coronary ischaemic disease. Their main effects are particularly suited for the management of effort-induced angina because of the reduction of oxygen demand they achieve. The clinical benefits of these drugs are highly reproducible and have been shown to improve overall clinical outcomes. Despite the availability of other, and newer antianginal drugs, treatment guidelines continue to recommend the use of beta-blockers and calcium channel blockers as first line therapies.
Literatur
2.
Zurück zum Zitat Wachter SB, Gilbert EM. Beta-adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application. Cardiology. 2012;122:104–12.CrossRefPubMed Wachter SB, Gilbert EM. Beta-adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application. Cardiology. 2012;122:104–12.CrossRefPubMed
3.
Zurück zum Zitat Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta Cardiol. 2010;65:565–70.CrossRefPubMed Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta Cardiol. 2010;65:565–70.CrossRefPubMed
5.
Zurück zum Zitat Reiter MJ. Cardiovascular drug class specificity: Beta-blockers. Prog Cardiovasc Dis. 2004;47:11–33.CrossRefPubMed Reiter MJ. Cardiovascular drug class specificity: Beta-blockers. Prog Cardiovasc Dis. 2004;47:11–33.CrossRefPubMed
6.
Zurück zum Zitat Husted SE, Ohman EM. Pharmacological and emerging therapies in the treatment of chronic angina. Lancet. 2015 Aug 15;386(9994):691–701. Husted SE, Ohman EM. Pharmacological and emerging therapies in the treatment of chronic angina. Lancet. 2015 Aug 15;386(9994):691–701.
7.
Zurück zum Zitat Montalescot G, Sechtem U, Achenbach S et al, and The Task Force Members. ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949–3003. Montalescot G, Sechtem U, Achenbach S et al, and The Task Force Members. ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949–3003.
8.
Zurück zum Zitat Frishman WH. β-adrenergic blockade in cardiovascular disease. J Cardiovasc Pharmacol Ther. 2013 Jul;18(4):310–9. Frishman WH. β-adrenergic blockade in cardiovascular disease. J Cardiovasc Pharmacol Ther. 2013 Jul;18(4):310–9.
9.
Zurück zum Zitat Chen-Scarabelli C, Saravolatz II L, Murad Y, et al. A critical review of the use of carvedilol in ischemic heart disease. Am J Cardiovasc Drugs. 2012;12:391–401.PubMed Chen-Scarabelli C, Saravolatz II L, Murad Y, et al. A critical review of the use of carvedilol in ischemic heart disease. Am J Cardiovasc Drugs. 2012;12:391–401.PubMed
10.
Zurück zum Zitat Frishman WH, Saunders E. Adrenergic blockers. J Clin Hypertens (Greenwich). 2011;13:649–53.CrossRef Frishman WH, Saunders E. Adrenergic blockers. J Clin Hypertens (Greenwich). 2011;13:649–53.CrossRef
11.
Zurück zum Zitat Frohlich ED, Tarazi RC, Dustan HP. Peripheral arterial insufficiency. A complication of beta-adrenergic blocking therapy. JAMA. 1969;208(13):2471–2.CrossRefPubMed Frohlich ED, Tarazi RC, Dustan HP. Peripheral arterial insufficiency. A complication of beta-adrenergic blocking therapy. JAMA. 1969;208(13):2471–2.CrossRefPubMed
12.
Zurück zum Zitat Salem SA, McDevitt DG. Central effects of beta-adrenoceptor antagonists. Clin Pharmacol Ther. 1983;33(1):52–7.CrossRefPubMed Salem SA, McDevitt DG. Central effects of beta-adrenoceptor antagonists. Clin Pharmacol Ther. 1983;33(1):52–7.CrossRefPubMed
13.
Zurück zum Zitat Frishman WH, Clark A, Johnson B. Effects of cardiovascular drugs on plasma lipids and lipoproteins. In: Frishman WH, Sonnenblick EH, editors. Cardiovascular Pharmacotherapeutics. New York, NY: McGraw Hill; 1997. p. 1515–59. Frishman WH, Clark A, Johnson B. Effects of cardiovascular drugs on plasma lipids and lipoproteins. In: Frishman WH, Sonnenblick EH, editors. Cardiovascular Pharmacotherapeutics. New York, NY: McGraw Hill; 1997. p. 1515–59.
14.
Zurück zum Zitat Elliott WJ, Meyer PM. Incident diabetes in clinical trials of anti- hypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–7.CrossRefPubMed Elliott WJ, Meyer PM. Incident diabetes in clinical trials of anti- hypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–7.CrossRefPubMed
15.
Zurück zum Zitat Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol. 2011;8:369–79.CrossRefPubMed Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol. 2011;8:369–79.CrossRefPubMed
16.
Zurück zum Zitat Jenkins NP, Keevil BG, Hutchinson IV, Brooks NH. Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. Am J Med. 2002 Mar;112(4):269–74. Jenkins NP, Keevil BG, Hutchinson IV, Brooks NH. Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. Am J Med. 2002 Mar;112(4):269–74.
17.
Zurück zum Zitat Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC. A new adrenergic betareceptor antagonist. Lancet. 1964;1:1080–1. Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC. A new adrenergic betareceptor antagonist. Lancet. 1964;1:1080–1.
18.
Zurück zum Zitat Hamer J, Grandjean T, Melendez L, Sowton GE. Effect of propranolol (Inderal) in angina pectoris: preliminary report. Br Med J. 1964;19:720–3.CrossRef Hamer J, Grandjean T, Melendez L, Sowton GE. Effect of propranolol (Inderal) in angina pectoris: preliminary report. Br Med J. 1964;19:720–3.CrossRef
19.
Zurück zum Zitat Warren SG, Brewer DL, Orgain ES. Long-term propranolol therapy for angina pectoris. Am J Cardiol. 1976 Mar 4;37(3):420–6. Warren SG, Brewer DL, Orgain ES. Long-term propranolol therapy for angina pectoris. Am J Cardiol. 1976 Mar 4;37(3):420–6.
20.
Zurück zum Zitat Hernández-Cañero A, González A, Cardonne A, Pérez-Medina T, Garcia-Barreto D. Effect of atenolol in angina pectoris of effort. Cor Vasa. 1972;20:99–103.PubMed Hernández-Cañero A, González A, Cardonne A, Pérez-Medina T, Garcia-Barreto D. Effect of atenolol in angina pectoris of effort. Cor Vasa. 1972;20:99–103.PubMed
21.
Zurück zum Zitat Narahara KA. Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris. Betaxolol Investigators Group Am J Cardiol. 1990;65:577–82.CrossRef Narahara KA. Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris. Betaxolol Investigators Group Am J Cardiol. 1990;65:577–82.CrossRef
22.
Zurück zum Zitat Kardas P. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol, a randomized controlled trial. Vasc Health Risk Manag. 2007;3:235–42.CrossRefPubMedPubMedCentral Kardas P. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol, a randomized controlled trial. Vasc Health Risk Manag. 2007;3:235–42.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Ryden L. Efficacy of epanolol versus metoprolol in angina pectoris, report from a Swedish multicentre study of exercise tolerance. J Intern Med. 1992;231:7–11.CrossRefPubMed Ryden L. Efficacy of epanolol versus metoprolol in angina pectoris, report from a Swedish multicentre study of exercise tolerance. J Intern Med. 1992;231:7–11.CrossRefPubMed
24.
Zurück zum Zitat Boberg J, Larsen FF, Pehrsson SK. The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity instable angina pectoris. The Visacor Study Group Clin Cardiol. 1992;15:591–5.CrossRef Boberg J, Larsen FF, Pehrsson SK. The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity instable angina pectoris. The Visacor Study Group Clin Cardiol. 1992;15:591–5.CrossRef
25.
Zurück zum Zitat Kaski JC, Rodriguez-Plaza L, Brown J, Maseri A. Efficacy of carvedilol (BM14, 190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia. Am J Cardiol. 1985;56:35–40.CrossRefPubMed Kaski JC, Rodriguez-Plaza L, Brown J, Maseri A. Efficacy of carvedilol (BM14, 190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia. Am J Cardiol. 1985;56:35–40.CrossRefPubMed
26.
Zurück zum Zitat Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The atenolol silent ischemia study (ASIST). Circulation. 1994;90:762–8.CrossRefPubMed Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The atenolol silent ischemia study (ASIST). Circulation. 1994;90:762–8.CrossRefPubMed
27.
Zurück zum Zitat The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The Beta-Blocker Pooling Project Research Group. Eur Heart J. 1988 Jan;9(1):8–16. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The Beta-Blocker Pooling Project Research Group. Eur Heart J. 1988 Jan;9(1):8–16.
28.
Zurück zum Zitat Dargie HJ, Ford I, Fox KM. Total ischaemic burden European trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET study group. Eur Heart J. 1996 Jan;17(1):104–12. Dargie HJ, Ford I, Fox KM. Total ischaemic burden European trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET study group. Eur Heart J. 1996 Jan;17(1):104–12.
29.
Zurück zum Zitat Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The angina prognosis study in Stockholm (APSIS). Eur Heart J. 1996;17:76–81.CrossRefPubMed Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The angina prognosis study in Stockholm (APSIS). Eur Heart J. 1996;17:76–81.CrossRefPubMed
30.
Zurück zum Zitat Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999 May 26;281(20):1927–36. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999 May 26;281(20):1927–36.
31.
Zurück zum Zitat Russek HI. Propranolol and isosorbide dinitrate synergism in angina pectoris. Am J Cardiol. 1968 Jan;21(1):44–54. Russek HI. Propranolol and isosorbide dinitrate synergism in angina pectoris. Am J Cardiol. 1968 Jan;21(1):44–54.
32.
Zurück zum Zitat Belsey J, Savelieva I, Mugelli A, Camm AJ. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015 Jul;22(7):837–48. Belsey J, Savelieva I, Mugelli A, Camm AJ. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015 Jul;22(7):837–48.
33.
Zurück zum Zitat Frishman WH, Sica DA. Calcium channel blockers. In: Frishman WH, Sonnenblick EH, Sica DA, editors. Cardiovascular Pharmacotherapeutics. New York: McGraw-Hill; 2003. Frishman WH, Sica DA. Calcium channel blockers. In: Frishman WH, Sonnenblick EH, Sica DA, editors. Cardiovascular Pharmacotherapeutics. New York: McGraw-Hill; 2003.
34.
Zurück zum Zitat Ong P, Sechtem U. Calcium Channel blockers. In: Avanzas P, Kaski JC, editors. Pharmacological treatment of chronic stable angina pectoris, current cardiovascular therapy. Switzerland: Springer International; 2015. Ong P, Sechtem U. Calcium Channel blockers. In: Avanzas P, Kaski JC, editors. Pharmacological treatment of chronic stable angina pectoris, current cardiovascular therapy. Switzerland: Springer International; 2015.
35.
Zurück zum Zitat Kaltenbach M, Schulz W, Kober G. Effects of nifedipine after intravenous and intracoronary administration. Am J Cardiol. 1979;44:832–8.CrossRefPubMed Kaltenbach M, Schulz W, Kober G. Effects of nifedipine after intravenous and intracoronary administration. Am J Cardiol. 1979;44:832–8.CrossRefPubMed
36.
Zurück zum Zitat Henry PD, Shuchleib R, Clark RE, Perez JE. Effect of nifedipine on myocardial ischemia. Am J Cardiol. 1979;44:817–24.CrossRefPubMed Henry PD, Shuchleib R, Clark RE, Perez JE. Effect of nifedipine on myocardial ischemia. Am J Cardiol. 1979;44:817–24.CrossRefPubMed
37.
Zurück zum Zitat Stone PH. Calcium antagonists for Prinzmetal’s variant angina, unstable angina and silent myocardial ischemia: therapeutic tool and probe for identification of pathophysiologic mechanisms. Am J Cardiol. 1987;59:101B–15B.CrossRefPubMed Stone PH. Calcium antagonists for Prinzmetal’s variant angina, unstable angina and silent myocardial ischemia: therapeutic tool and probe for identification of pathophysiologic mechanisms. Am J Cardiol. 1987;59:101B–15B.CrossRefPubMed
38.
Zurück zum Zitat Stone PH, Gibson RS, Glasser SP, et al. Comparison of propanolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina: differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. Circulation. 1990;82:1962–72.CrossRefPubMed Stone PH, Gibson RS, Glasser SP, et al. Comparison of propanolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina: differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. Circulation. 1990;82:1962–72.CrossRefPubMed
39.
Zurück zum Zitat Antman E, Muller J, Goldberg S, et al. Nifedipine therapy for coronary-artery spasm: experience in 127 patients. N Engl J Med. 1980;302:1269–73.CrossRefPubMed Antman E, Muller J, Goldberg S, et al. Nifedipine therapy for coronary-artery spasm: experience in 127 patients. N Engl J Med. 1980;302:1269–73.CrossRefPubMed
40.
Zurück zum Zitat Ezekowitz MD, Hossack K, Mehta JL, et al. Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. Am Heart J. 1995;129:527–35.CrossRefPubMed Ezekowitz MD, Hossack K, Mehta JL, et al. Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. Am Heart J. 1995;129:527–35.CrossRefPubMed
41.
Zurück zum Zitat Boman K, Saetre H, Karlsson LG, et al. Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris. Eur J Clin Pharmacol. 1995;49:27–30.CrossRefPubMed Boman K, Saetre H, Karlsson LG, et al. Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris. Eur J Clin Pharmacol. 1995;49:27–30.CrossRefPubMed
42.
Zurück zum Zitat Brogden RN, Benfield P. Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs. 1996;51:792–819.CrossRefPubMed Brogden RN, Benfield P. Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs. 1996;51:792–819.CrossRefPubMed
43.
Zurück zum Zitat Cohn PF. Concomitant use of nitrates, calcium channel blockers, and beta-blockers for optimal antianginal therapy. Clin Cardiol. 1994;17:415–21.CrossRefPubMed Cohn PF. Concomitant use of nitrates, calcium channel blockers, and beta-blockers for optimal antianginal therapy. Clin Cardiol. 1994;17:415–21.CrossRefPubMed
44.
Zurück zum Zitat Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol. 1996;27:311.CrossRefPubMed Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol. 1996;27:311.CrossRefPubMed
45.
Zurück zum Zitat Poole-Wilson PA, Lubsen J, Kirwan BA et al, On behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849–857. Poole-Wilson PA, Lubsen J, Kirwan BA et al, On behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849–857.
46.
47.
Zurück zum Zitat Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004 Nov 10;292(18):2217–25. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004 Nov 10;292(18):2217–25.
48.
Zurück zum Zitat Johnson SM, Mauritson DR, Corbett JR, et al. Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. Am J Med. 1981;71:443.CrossRefPubMed Johnson SM, Mauritson DR, Corbett JR, et al. Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. Am J Med. 1981;71:443.CrossRefPubMed
49.
Zurück zum Zitat Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-Trandolapril study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 3;290(21):2805–16. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-Trandolapril study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 3;290(21):2805–16.
50.
Zurück zum Zitat Ried LD, Tueth MJ, Handberg E, Kupfer S, Pepine CJ, INVEST Study Group. A study of antihypertensive drugs and depressive symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension treatment strategy in the international verapamil SR-Trandolapril study (INVEST). Psychosom Med. 2005 May-Jun;67(3):398–406. Ried LD, Tueth MJ, Handberg E, Kupfer S, Pepine CJ, INVEST Study Group. A study of antihypertensive drugs and depressive symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension treatment strategy in the international verapamil SR-Trandolapril study (INVEST). Psychosom Med. 2005 May-Jun;67(3):398–406.
51.
Zurück zum Zitat Hossack KF, Pool PE, Steele P, et al. Efficacy of diltiazem in angina on effort: a multicenter trial. Am J Cardiol. 1982;49:567.CrossRefPubMed Hossack KF, Pool PE, Steele P, et al. Efficacy of diltiazem in angina on effort: a multicenter trial. Am J Cardiol. 1982;49:567.CrossRefPubMed
52.
Zurück zum Zitat Strauss WE, McIntyre KM, Parisi AF, Shapiro W. Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: report of a cooperative clinical trial. Am J Cardiol. 1982;49:560.CrossRefPubMed Strauss WE, McIntyre KM, Parisi AF, Shapiro W. Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: report of a cooperative clinical trial. Am J Cardiol. 1982;49:560.CrossRefPubMed
53.
Zurück zum Zitat Sagie A, Strasberg B, Kusnieck J, Sclarovsky S. Symptomatic bradycardia induced by the combination of oral diltiazem and beta blockers. Clin Cardiol. 1991 Apr;14(4):314–6. Sagie A, Strasberg B, Kusnieck J, Sclarovsky S. Symptomatic bradycardia induced by the combination of oral diltiazem and beta blockers. Clin Cardiol. 1991 Apr;14(4):314–6.
54.
Zurück zum Zitat Leon MB, Rosing DR, Bonow RO, Epstein SE. Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris. Am J Cardiol. 1985 Jan 25;55(3):69B–80B. Leon MB, Rosing DR, Bonow RO, Epstein SE. Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris. Am J Cardiol. 1985 Jan 25;55(3):69B–80B.
55.
Zurück zum Zitat Dunselman PH, van Kempen LH, Bouwens LH, et al. Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol. 1998;81:128.CrossRefPubMed Dunselman PH, van Kempen LH, Bouwens LH, et al. Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol. 1998;81:128.CrossRefPubMed
56.
Zurück zum Zitat Beltrame JF, Crea F, Kaski JC et al. 2015 Aug International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 4. pii: ehv351. Epub ahead of print. Beltrame JF, Crea F, Kaski JC et al. 2015 Aug International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 4. pii: ehv351. Epub ahead of print.
57.
Zurück zum Zitat Chahine RA. The calcium antagonists in vasospastic angina. J Cardiovasc Pharmacol. 1991;17(Suppl 1):S40–2.CrossRefPubMed Chahine RA. The calcium antagonists in vasospastic angina. J Cardiovasc Pharmacol. 1991;17(Suppl 1):S40–2.CrossRefPubMed
58.
Zurück zum Zitat Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. REACH registry investigators. β-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 Oct 3;308(13):1340–9. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. REACH registry investigators. β-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 Oct 3;308(13):1340–9.
59.
Zurück zum Zitat Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):872–81. Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):872–81.
Metadaten
Titel
Beta-Blockers and Calcium Channel Blockers: First Line Agents
verfasst von
Isaac Pascual
Cesar Moris
Pablo Avanzas
Publikationsdatum
30.08.2016
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 4/2016
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-016-6682-1

Weitere Artikel der Ausgabe 4/2016

Cardiovascular Drugs and Therapy 4/2016 Zur Ausgabe

Neu im Fachgebiet Kardiologie

Nach dem Nitrospray fünf Minuten mit der Kardio-CT warten!

19.07.2024 Koronare Herzerkrankung Nachrichten

Nach Verabreichung von sublingualem Nitrospray vor einer CT-Koronarangiografie sollte man unbedingt die in Leitlinien empfohlene Wartezeit einhalten, rät ein kardiologisches Team aus Belgien.

Welche Antikoagulation bei Vorhofflimmern und Leberzirrhose?

19.07.2024 Leberzirrhose Nachrichten

Bei einer Auswertung von US-Versicherungsdaten ging es um die Frage, welche Antikoagulation –  Apixaban, Rivaroxaban oder Warfarin – bei Personen mit Leberzirrhose und Vorhofflimmern unterm Strich die beste Prophylaxe-Option ist.     

Mehrgefäßstenosen einzeitig oder zweizeitig eröffnen?

18.07.2024 Gefäßstenosen Nachrichten

Nach einem Herzinfarkt mit Mehrgefäßerkrankung sind bessere Ergebnisse zu erwarten, wenn alle stenotischen Abschnitte revaskularisiert werden. Sollte das in einer oder in mehreren Sitzungen geschehen? Eine Metaanalyse gibt eine klare Antwort.

Erste zielgerichtete Therapie zur Behandlung der hypertrophen obstruktiven Kardiomyopathie

18.07.2024 Kardiomyopathie Nachrichten

Mit Mavacamten von Bristol Myers Squibb ist erstmals eine zielgerichtete Therapie der hypertrophen obstruktiven Kardiomyopathie (HOCM) verfügbar. Der Myosin-Inhibitor verhindert die bei HOCM übermäßige Bildung von Aktin-Myosin-Querbrücken und verbessert die Symptomatik und die Lebensqualität von Betroffenen.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.